A lipoxygenase inhibitor in breast cancer brain metastases
The complication of multiple brain metastases in breast cancer patients is a life threatening condition with limited success following standard therapies. The arachidonate lipoxygenase pathway appears to play a role in brain tumor growth as well as inhibition of apoptosis in in-vitro studies. The down regulation of these arachidonate lipoxygenase growth stimulating products therefore appeared to be a worthwile consideration for testing in brain metastases not responding to standard therapy. Boswellia serrata, a lipoxygenase inhibitor was applied for this inhibition. Multiple brain metastases were successfully reversed using this method in a breast cancer patient who had not shown improvement after standard therapy. The results suggest a potential new area of therapy for breast cancer patients with brain metastases that may be useful as an adjuvant to our standard therapy.
KeywordsCancer Lipoxygenase Boswellia serrata Oxidoreductase inhibitor LOX inhibitors Lipoxygenase inhibitor Brain Cancer Breast Cancer Metastases Breast Cancer Remission Arachidonate: Oxygen oxidoreductase Herceptin
This work was supported by The Samuel Freeman Charitable Trust and the M.J. and Caral G. Lebworth Foundation. Special Thanks to Dr. Albert Scheller (deceased 9/’05) of the Leonardis Oncology Clinic in Bad Heilbrunn, Germany for his excellent additional care of this patient, and Dr. Ursula Jacobs for her continued assistance in therapy.
- 4.Giller CA, Berger BD (2005) New frontiers in radiosurgery for the brain and body. BUMC Proc 18:311–319Google Scholar